The University of Tokyo · Medicine
Professor Satoru Miyawaki's research lab focuses on cerebrovascular diseases, particularly intracranial atherosclerotic stenosis (ICASO) and moyamoya disease (MMD), with a strong emphasis on the genetic and pathological mechanisms underlying these conditions. The lab investigates the role of the RNF213 c.14576G>A variant as a high-risk allele for ICASO, exploring its association with vascular remodeling and neuronal cell death. Additionally, the lab integrates histopathological analysis with imaging mass spectrometry (IMS) to uncover early molecular changes in ischemic brain injury, particularly in the hippocampal CA1 region. The research also extends to perioperative cerebrovascular and cardiac complications in carotid interventions, especially in elderly patients.
Figures are computed from collected data and may differ slightly.
A particular subset of patients with various phenotypes of ICASO has a common genetic variant, RNF213 c.14576G>A, indicating that RNF213 c.14576G>A variant is a high-risk allele for ICASO.
The present study indicates that a particular subset of Japanese patients with non-MMD ICASO has a genetic variant associated with MMD. Therefore, we propose the existence of a new entity of ICASO caused by the c.14576G>A variant in RNF213.
This study indicates that RNF213 c.14576G>A is associated with negative remodeling of ICAS.
Histopathology and IMS can provide comprehensive and complementary information on cell death mechanisms in the hippocampal CA1 after global ischemia. IMS provided novel data on molecular changes in phospholipids immediately after TGI. Increased level of PC (diacyl-16:0/22:6) in the pyramidal cell layer of hippocampal CA1 prior to the histopathological change may represent an early step in delayed neuronal death mechanisms.
Ischemic cardiac complication is one of the major perioperative complications of surgical treatment for cervical carotid stenosis, carotid endarterectomy (CEA), and carotid artery stenting (CAS), and may greatly affect surgical outcome, especially in elderly patients aged ≥ 80 years. We retrospectively analyzed the records of 259 patients (34 patients aged ≥ 80 years) treated by CEA and 61 patients (12 patients aged ≥ 80 years) treated by CAS at Aizu Chuo Hospital from January 2000 to September
Open papers in the app to read, cite, and organize with AI.
